StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The integration into OncoEMR MPI with Flatiron expands the addressable testing base and could drive higher Haystack MRD test volumes and related CGP services, supporting revenue growth and utilization of Quest's oncology test portfolio. The nationwide rollout in H2 2026 could accelerate this ramp, though adoption delays and payer coverage remain risks.
What happened, with direct paths to the underlying reporting
Quest Diagnostics will integrate its Haystack MRD ctDNA test and CGP tests into Flatiron Health's OncoEMR MPI, via a pilot with American Oncology Network and other community providers. The rollout will enable about 4,700 Flatiron clinicians across 1,600 sites to order Quest tests more easily, with a nationwide launch planned in H2 2026. This should boost Haystack MRD adoption and potential DGX revenue, while reducing clinician workflow friction.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.